Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody Read More »
